Sophie Anne Millar

Sophie Anne Millar


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2018 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
SMSophie Anne Millar
Sophie Anne Millar
NSNicole L. Stone
Nicole L. Stone
AYAndrew S. Yates
Andrew S. Yates
SOSaoirse O'Sullivan
Saoirse O'Sullivan
Background: Cannabidiol is being pursued as a therapeutic treatment for multiple conditions, usually by oral delivery. Animal studies suggest oral bioavailability is low, but literature in humans is not sufficient. The aim of this review was to collate published data in this area. Methods: A systematic search of PubMed and EMBASE (including MEDLINE) was conducted to retrieve all articles reporting pharmacokinetic data of CBD in humans. Results: Of 792 articles retireved, 24 included pharmacokinetic parameters in humans. The half-life of cannabidiol was reported between 1.4 and 10.9 h after oromucosal spray, 2–5 days after chronic oral administration, 24 h after i.v., and 31 h after smoking. Bioavailability following smoking was 31% however no other studies attempted to report the absolute bioavailability of CBD following other routes in humans, despite i.v formulations being available. The area-under-the-curve and Cmax increase in dose-dependent manners and are reached quicker following smoking/inhalation compared to oral/oromucosal routes. Cmax is increased during fed states and in lipid formulations. Tmax is reached between 0 and 4 h. Conclusions: This review highlights the paucity in data and some discrepancy in the pharmacokinetics of cannabidiol, despite its widespread use in humans. Analysis and understanding of properties such as bioavailability and half-life is critical to future therapeutic success, and robust data from a variety of formulations is required.

20 June 2019 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
SMSophie Anne Millar
Sophie Anne Millar
NSN.L. Stone
N.L. Stone
ZBZ.D. Bellman
Z.D. Bellman
AYA.S. Yates
A.S. Yates
TET.J. England
T.J. England
SOSaoirse O'Sullivan
Saoirse O'Sullivan
Aims Cannabidiol (CBD) is a cannabis‐derived medicinal product with potential application in a wide‐variety of contexts; however, its effective dose in different disease states remains unclear. This review aimed to investigate what doses have been applied in clinical populations, in order to understand the active range of CBD in a variety of medical contexts. Methods Publications involving administration of CBD alone were collected by searching PubMed, EMBASE and ClinicalTrials.gov. Results A total of 1038 articles were retrieved, of which 35 studies met inclusion criteria covering 13 medical contexts. Twenty‐three studies reported a significant improvement in primary outcomes (e.g. psychotic symptoms, anxiety, seizures), with doses ranging between <1 and 50 mg/kg/d. Plasma concentrations were not provided in any publication. CBD was reported as well tolerated and epilepsy was the most frequently studied medical condition, with all 11 studies demonstrating positive effects of CBD on reducing seizure frequency or severity (average 15 mg/kg/d within randomised controlled trials). There was no signal of positive activity of CBD in small randomised controlled trials (range n = 6–62) assessing diabetes, Crohn's disease, ocular hypertension, fatty liver disease or chronic pain. However, low doses (average 2.4 mg/kg/d) were used in these studies. Conclusion This review highlights that CBD has a potential wide range of activity in several pathologies. Pharmacokinetic studies as well as conclusive phase III trials to elucidate effective plasma concentrations within medical contexts are severely lacking and highly encouraged.

28 August 2020 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
SMSophie Anne Millar
Sophie Anne Millar
RMRyan Francis Maguire
Ryan Francis Maguire
AYAndrew Yates
Andrew Yates
SOSaoirse O'Sullivan
Saoirse O'Sullivan
Cannabidiol (CBD) has substantial therapeutic potential, but its development as an effective drug by the pharmaceutical industry is hindered by intrinsic characteristics such as low bioavailability, low water solubility, and variable pharmacokinetic profiles. Importantly, lack of patentability of the drug substance also limits the likelihood of an expensive, full development programme in anything other than orphan indications. Potential avenues to overcome these issues with CBD include self-emulsifying drug delivery systems, improved crystal formulations and other solid-state delivery formulations, which are mostly in the pre-clinical or early clinical stages of development. This review identifies issues compromising current delivery of solid-state CBD, and how advanced pharmaceutical development strategies can enable CBD to realise the full potential as a successful therapeutic agent.

24 February 2017 in Frontiers in Pharmacology
Verified
Journal Article
Open access
SSSalahaden R Sultan
Salahaden R Sultan
SMSophie Anne Millar
Sophie Anne Millar
TETimothy J. England
Timothy J. England
SOSaoirse O'Sullivan
Saoirse O'Sullivan
Despite cannabidiol (CBD) having numerous cardiovascular effects in vitro, its haemodynamic effects in vivo are unclear. Nonetheless, the clinical use of CBD (Epidiolex) is becoming more widespread. The aim of this systematic review was to establish whether CBD is associated with changes in haemodynamics in vivo. 25 studies that assessed the haemodynamic effects of CBD (from PubMed, Medline and EMBASE) were systematically reviewed and meta-analysed. Data on blood pressure (BP), heart rate (HR) and blood flow (BF) were extracted and analysed using random effects models. 22 publications assessed BP and HR among 6 species (BP n=344 and HR n=395), and 5 publications assessed BF in 3 species (n=56) after acute dosing of CBD. Chronic dosing was assessed in 4 publications in 3 species (total subjects BP, n=6; HR, n=27; BF, n=3). Acute CBD dosing had no effect on BP or HR under control conditions. Similarly, chronic dosing with CBD had no effect on HR. In models of stress, acute CBD administration significantly reduced the increase in BP and HR induced by stress (BP, mean difference (MD) -3.54, 95% CI -5.19, -1.9, p<0.0001; HR, MD -16.23, 95% CI -26.44, -6.02, p=0.002). In mouse models of stroke, CBD significantly increased cerebral blood flow (CBF, standardised mean difference (SMD) 1.62, 95% CI 0.41, 2.83, p=0.009). Heterogeneity among the studies was present, there was no publication bias except in HR of control and stressful conditions after acute CBD dosing, and median study quality was 5 out of 9 (ranging from 1 to 8). From the limited data available, we conclude that acute and chronic administration of CBD had no effect on BP or HR under control conditions, but reduces BP and HR in stressful conditions, and increases cerebral blood flow (CBF) in mouse models of stroke. Further studies are required to fully understand the potential haemodynamic effects of CBD in humans under normal and pathological conditions.

31 July 2017 in Frontiers in Endocrinology
Verified
Journal Article
Open access
SMSophie Anne Millar
Sophie Anne Millar
HPHinal Patel
Hinal Patel
SASusan I. Anderson
Susan I. Anderson
TETimothy J. England
Timothy J. England
SOSaoirse O'Sullivan
Saoirse O'Sullivan
Background: Osteocalcin is an intriguing hormone, concomitantly being the most abundant non-collagenous peptide found in the mineralised matrix of bone, and expanding the endocrine function of the skeleton with far-reaching extra-osseous effects. A new line of enquiry between osteocalcin and vascular calcification has emerged in response to observations that the mechanism of vascular calcification resembles that of bone mineralisation. To date, studies have reported mixed results. This systematic review and meta-analysis aimed to identify any association between osteocalcin and vascular calcification and atherosclerosis. Methods and results: Databases were searched for original, peer reviewed human studies. A total of 1453 articles were retrieved, of which 46 met the eligibility criteria. Overall 26 positive, 17 negative, and 29 neutral relationships were reported for assessments between osteocalcin (either concentration in blood, presence of osteocalcin positive cells, or histological staining for osteocalcin) and extent of calcification or atherosclerosis. Studies which measured osteocalcin positive cells or histological staining for osteocalcin reported positive relationships (11 studies). A higher percentage of Asian studies found a negative relationship (36%) in contrast to European studies (6%). Studies examining carboxylated and undercarboxylated forms of osteocalcin in the blood failed to report consistent results. The meta-analysis found no significant difference between osteocalcin concentration in the blood between patients with ‘atherosclerosis’ and control (p=0.13, n=1197). Conclusions: No definitive association was determined between osteocalcin and vascular calcification or atherosclerosis, however, the presence of osteocalcin positive cells and histological staining had a consistent positive correlation with calcification or atherosclerosis. The review highlighted several themes which may influence osteocalcin within differing populations leading to inconclusive results. Large, longitudinal studies are required to further current understanding of the clinical relevance of osteocalcin in vascular calcification and atherosclerosis.

26 November 2018 in Frontiers in Behavioral Neuroscience
Verified
Journal Article
Open access
PDF file
NSNicole L. Stone
Nicole L. Stone
SMSophie Anne Millar
Sophie Anne Millar
PHPhilip Herrod
Philip Herrod
DBDavid A. Barrett
David A. Barrett
COCatharine A. Ortori
Catharine A. Ortori
SOSaoirse O'Sullivan
Saoirse O'Sullivan
The euphoric feeling described after running is, at least in part, due to increased circulating endocannabinoids (eCBs). eCBs are lipid signaling molecules involved in reward, appetite, mood, memory and neuroprotection. The aim of this study was to investigate whether activities other than running can increase circulating eCBs. Nine healthy female volunteers (mean 61 years) were recruited from a local choir. Circulating eCBs, haemodynamics, mood and hunger ratings were measured before and immediately after 30 min of dance, reading, singing or cycling in a fasted state. Singing increased plasma levels of anandamide (AEA) by 42% (P < 0.05), palmitoylethanolamine (PEA) by 53% (P < 0.01) and oleoylethanolamine (OEA) by 34% (P < 0.05) and improved positive mood and emotions (P < 0.01), without affecting hunger scores. Dancing did not affect eCB levels or hunger ratings, but decreased negative mood and emotions (P < 0.01). Cycling increased OEA levels by 26% (P < 0.05) and tended to decrease how hungry volunteers felt, without affecting mood. Reading increased OEA levels by 28% (P < 0.01) and increased the desire to eat. Plasma AEA levels were positively correlated with how full participants felt (P < 0.05). Plasma OEA levels were positively correlated with positive mood and emotions (P < 0.01). All three ethanolamines were positively correlated with heart rate (HR; P < 0.0001). These data suggest that activities other than running can increase plasma eCBs associated with changes in mood or appetite. Increases in eCBs may underlie the rewarding and pleasurable effects of singing and exercise and ultimately some of the long-term beneficial effects on mental health, cognition and memory.